TCGA-CQ-7063-01A-11R-2403-07
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
- sex
- female
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- INTERFERON_ALPHA_RESPONSE+0.740
- INTERFERON_GAMMA_RESPONSE+0.640
- ALLOGRAFT_REJECTION+0.560
- IL6_JAK_STAT3_SIGNALING+0.510
- TNFA_SIGNALING_VIA_NFKB+0.510
- INFLAMMATORY_RESPONSE+0.440
- APICAL_SURFACE+0.410
- COMPLEMENT+0.380
- TGF_BETA_SIGNALING+0.380
- IL2_STAT5_SIGNALING+0.350
Top 10 suppressed
- E2F_TARGETS-0.300
- OXIDATIVE_PHOSPHORYLATION-0.270
- MYOGENESIS-0.260
- EPITHELIAL_MESENCHYMAL_TRANSITION-0.230
- MYC_TARGETS_V1-0.200
- DNA_REPAIR-0.180
- SPERMATOGENESIS-0.160
- ADIPOGENESIS-0.120
- G2M_CHECKPOINT-0.120
- GLYCOLYSIS-0.120
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | TCGA-BA-5556-01A-01R-1514-07 | — | — | 0.923 |
| 2 | TCGA-CV-7427-01A-11R-2081-07 | — | — | 0.859 |
| 3 | TCGA-K4-A6FZ-01A-11R-A31N-07 | — | — | 0.856 |
| 4 | TCGA-UY-A9PA-01A-11R-A38B-07 | — | — | 0.855 |
| 5 | TCGA-CR-7395-01A-11R-2016-07 | — | — | 0.844 |
| 6 | SRR23303760 | — | — | 0.828 |
| 7 | SRR8613765 | — | D | 0.827 |
| 8 | TCGA-B6-A0WS-01A-11R-A115-07 | — | A | 0.825 |
| 9 | TCGA-CV-6952-01A-11R-1915-07 | — | — | 0.821 |
| 10 | SRR8518406 | — | D | 0.819 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 34 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| INTERFERON_ALPHA_RESPONSE | 0.740 | Inavolisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.640 | Idelalisib | — uncovered |
| ALLOGRAFT_REJECTION | 0.560 | Idelalisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.510 | Inavolisib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.510 | Inavolisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.440 | Idelalisib | — uncovered |
| APICAL_SURFACE | 0.410 | Temsirolimus | — uncovered |
| COMPLEMENT | 0.380 | Inavolisib | — uncovered |
| TGF_BETA_SIGNALING | 0.380 | Inavolisib | — uncovered |
| IL2_STAT5_SIGNALING | 0.350 | Idelalisib | — uncovered |
| P53_PATHWAY | 0.340 | Idelalisib | — uncovered |
| KRAS_SIGNALING_UP | 0.320 | Inavolisib | — uncovered |
| APOPTOSIS | 0.280 | Idelalisib | — uncovered |
| CHOLESTEROL_HOMEOSTASIS | 0.270 | Remibrutinib | — uncovered |
| PI3K_AKT_MTOR_SIGNALING | 0.270 | Inavolisib | — uncovered |
| MITOTIC_SPINDLE | 0.260 | Inavolisib | — uncovered |
| APICAL_JUNCTION | 0.220 | Inavolisib | — uncovered |
| HEME_METABOLISM | 0.180 | Temsirolimus | — uncovered |
| NOTCH_SIGNALING | 0.180 | Inavolisib | — uncovered |
| ESTROGEN_RESPONSE_LATE | 0.160 | Idelalisib | — uncovered |